CD19, a B-cell surface protein ... and several non-Hodgkin lymphomas. This universal expression and specificity for a single cell lineage have rendered CD19 an appealing target for antibody ...

we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal ...

It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell ... detect the anti-CD19 CAR expression on the surface of transduced T cells. These proteins have been ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech ... of 69% among 13 evaluable patients with diffuse large B-cell lymphoma. Galapagos splits in 2, laying off 40% ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...